Literature DB >> 20973931

Oncogenic RAF: a brief history of time.

David Solit1, Neal Rosen.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20973931     DOI: 10.1111/j.1755-148X.2010.00779.x

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN: 1755-1471            Impact factor:   4.693


× No keyword cloud information.
  5 in total

1.  Markers of resistance to anti-EGFR therapy in colorectal cancer.

Authors:  Walid Shaib; Reena Mahajan; Bassel El-Rayes
Journal:  J Gastrointest Oncol       Date:  2013-09

2.  Effective inhibition of melanoma by BI-69A11 is mediated by dual targeting of the AKT and NF-κB pathways.

Authors:  Yongmei Feng; Elisa Barile; Surya K De; John L Stebbins; Apple Cortez; Pedro Aza-Blanc; Jessie Villanueva; Meenhard Heryln; Stan Krajewski; Maurizio Pellecchia; Ze'ev A Ronai; Gary G Chiang
Journal:  Pigment Cell Melanoma Res       Date:  2011-06-06       Impact factor: 4.693

3.  Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma.

Authors:  Molly Yancovitz; Adam Litterman; Joanne Yoon; Elise Ng; Richard L Shapiro; Russell S Berman; Anna C Pavlick; Farbod Darvishian; Paul Christos; Madhu Mazumdar; Iman Osman; David Polsky
Journal:  PLoS One       Date:  2012-01-03       Impact factor: 3.240

Review 4.  Reversal of Resistance in Targeted Therapy of Metastatic Melanoma: Lessons Learned from Vemurafenib (BRAFV600E-Specific Inhibitor).

Authors:  Antoni Xavier Torres-Collado; Jeffrey Knott; Ali R Jazirehi
Journal:  Cancers (Basel)       Date:  2018-05-24       Impact factor: 6.639

5.  Macrophage migration inhibitory factor engages PI3K/Akt signalling and is a prognostic factor in metastatic melanoma.

Authors:  Camila S Oliveira; Charles E de Bock; Timothy J Molloy; Elham Sadeqzadeh; Xin Yan Geng; Peter Hersey; Xu Dong Zhang; Rick F Thorne
Journal:  BMC Cancer       Date:  2014-08-29       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.